FDA releases HFP priorities: All eyes on modernizing dietary supplement oversight, GRAS, NDIs - NutraIngredients.com
FDA's Human Foods Program (HFP) priorities include modernizing dietary supplement oversight, GRAS, and NDI processes, signaling potential regulatory changes for supplement brands, contract manufacturers, private-label sellers, and ingredient suppliers.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; no immediate deadline but proactive monitoring recommended.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA announced HFP priorities focusing on modernizing dietary supplement oversight, GRAS, and NDI notifications, which may lead to stricter labeling, safety, and notification requirements.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Monitor FDA announcements for specific rule changes; review current labeling and NDI submissions for compliance; engage with trade associations for updates.
Deadline
Ongoing; no immediate deadline but proactive monitoring recommended.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- Warning Letters | FDA
- FDA Advisory No.2026-0735 || Public Health Warning on the Presence of Sildenafil Citrate in TURBO Maca and Clavo Huasca Dietary Supplement Capsules for Men with Lot Number 24TRB1102 - Food and Drug Administration - fda.gov.ph
- FDA Advisory No.2026-0162-A || Lifting the Advisory on the Registered Food Product LUXE SKIN BEAUTY TALKS L’ANNA Premium Oral Sunblock + Stem Cell Dietary Supplement “Public Health Warning Against the Purchase and Consumption of the Unregis - fda.gov.ph
- The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire